Loqus23 Therapeutics said it is advancing LQT-23 for development as a first-in-class oral treatment for Huntington’s disease. The company said LQT-23 has the potential to slow or halt the onset and progression of the disease, and it plans to submit applications seeking permission to bring the experimental therapy…